← FDA DRUG APPROVALS

FDA NDA · NDA020635

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor: JANSSEN PHARMS

APPLICATION
NDA020635
TYPE
NDA
ORIGINAL APPROVAL
1996-12-20
LATEST ACTION
2017-02-08
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER · ReferenceDiscontinued
LEVOFLOXACIN EQ 750MG/150ML (EQ 5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER · ReferenceDiscontinued
LEVOFLOXACIN EQ 500MG/100ML (EQ 5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
LEVAQUIN · ReferenceDiscontinued
LEVOFLOXACIN EQ 500MG/20ML (EQ 25MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
LEVAQUIN · ReferenceDiscontinued
LEVOFLOXACIN EQ 750MG/30ML (EQ 25MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER · ReferenceDiscontinued
LEVOFLOXACIN EQ 250MG/50ML (EQ 5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION

Approval history

2017-02-08Labeling · Supplement 74 · standardLetterAP
2016-07-26Labeling · Supplement 73 · standardLetterAP
2014-05-23Labeling · Supplement 72 · standardLetterAP
2013-08-14Labeling · Supplement 71 · 901 requiredLetterAP
2012-04-27Efficacy · Supplement 67 · priorityReviewAP
2011-10-11REMS · Supplement 70ReviewAP
2011-10-11Labeling · Supplement 68 · unknownReviewAP
2011-06-09Labeling · Supplement 65 · unknownLabelAP
2011-02-25Labeling · Supplement 64 · 901 requiredLabelAP
2009-04-27Labeling · Supplement 58 · standardLetterAP
2009-03-12Labeling · Supplement 59 · standardLetterAP
2008-10-03Labeling · Supplement 57 · standardLabelAP
2008-05-05Efficacy · Supplement 51 · unknownSummary ReviewAP
2008-04-16Labeling · Supplement 55 · standardLabelAP
2007-12-13Labeling · Supplement 54 · standardLabelAP
2007-11-16Labeling · Supplement 53 · standardLetterAP
2007-11-15Labeling · Supplement 52 · standardLetterAP
2007-09-14Efficacy · Supplement 44 · unknownLetterAP
2007-09-11Efficacy · Supplement 46 · priorityLetterAP
2007-06-19Labeling · Supplement 48 · standardLetterAP
2007-05-31Labeling · Supplement 45 · standardLetterAP
2007-05-10Labeling · Supplement 47 · standardLabelAP
2006-06-23Labeling · Supplement 43 · standardPediatric Medical ReviewAP
2006-01-20Labeling · Supplement 42 · standardLabelAP
2005-08-04Efficacy · Supplement 38 · unknownLetterAP
2004-11-24Efficacy · Supplement 35 · priorityLetterAP
2004-11-04Labeling · Supplement 37 · standardLetterAP
2004-09-14Labeling · Supplement 34 · standardLabelAP
2004-09-14Labeling · Supplement 33 · standardLabelAP
2004-07-14Efficacy · Supplement 30 · priorityLetterAP
2004-03-05Labeling · Supplement 29 · standardLabelAP
2003-10-23Efficacy · Supplement 27 · standardReviewAP
2003-05-23Efficacy · Supplement 26 · standardReviewAP
2002-11-21Manufacturing (CMC) · Supplement 25 · standardAP
2002-11-06Manufacturing (CMC) · Supplement 24 · standardAP
2002-10-30Efficacy · Supplement 22 · priorityLetterAP
2002-01-11Manufacturing (CMC) · Supplement 21 · standardAP
2001-12-18Labeling · Supplement 20 · standardReviewAP
2001-12-18Labeling · Supplement 12 · standardLabelAP
2001-12-18Labeling · Supplement 19 · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →